Abe Y - Search Results

1

Immunomodulatory drugs in the treatment of multiple myeloma.

Abe Y, Ishida T. Abe Y, et al. Jpn J Clin Oncol. 2019 Aug 1;49(8):695-702. doi: 10.1093/jjco/hyz083. Jpn J Clin Oncol. 2019. PMID: 31187860 Review.

2

Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K, Suzuki K. Abe Y, et al. Exp Hematol. 2009 Aug;37(8):956-68. doi: 10.1016/j.exphem.2009.04.008. Epub 2009 May 4. Exp Hematol. 2009. PMID: 19409955 Free article. Clinical Trial.

3

[Increased level of KL-6 in a BJP-λ-type multiple myeloma patient with poor prognosis].

Nakagawa Y, Iizuka H, Nishiyama S, Abe Y, Kusaka S, Sekine R, Suzuki K. Nakagawa Y, et al. Among authors: abe y. Rinsho Ketsueki. 2012 May;53(5):521-5. Rinsho Ketsueki. 2012. PMID: 22728554 Japanese.

4

[Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia].

Hamano A, Shingaki S, Abe Y, Miyazaki K, Sekine R, Nakagawa Y, Tsukada N, Hattori Y, Suzuki K. Hamano A, et al. Among authors: abe y. Rinsho Ketsueki. 2014 Apr;55(4):428-35. Rinsho Ketsueki. 2014. PMID: 24850453 Japanese.

5

[Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection].

Honda Y, Inoue J, Shingaki S, Miyazaki K, Abe Y, Sekine E, Iki S, Tsukada N, Suzuki K. Honda Y, et al. Among authors: abe y. Rinsho Ketsueki. 2014 May;55(5):570-2. Rinsho Ketsueki. 2014. PMID: 24881924 Japanese.

6

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.

Suzuki K, Ogura M, Abe Y, Suzuki T, Tobinai K, Ando K, Taniwaki M, Maruyama D, Kojima M, Kuroda J, Achira M, Iizuka K. Suzuki K, et al. Among authors: abe y. Int J Hematol. 2015 Mar;101(3):286-94. doi: 10.1007/s12185-015-1743-y. Epub 2015 Feb 6. Int J Hematol. 2015. PMID: 25655379 Clinical Trial.

7

[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].

Tsukada N, Shingaki S, Ikeda M, Miyazaki K, Meshitsuka S, Yoshiki Y, Abe Y, Suzuki K. Tsukada N, et al. Among authors: abe y. Rinsho Ketsueki. 2015 Jul;56(7):895-900. doi: 10.11406/rinketsu.56.895. Rinsho Ketsueki. 2015. PMID: 26256927 Japanese.

8

[Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma].

Tsukada N, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Yoshiki Y, Abe Y, Suzuki K. Tsukada N, et al. Among authors: abe y. Rinsho Ketsueki. 2015 Aug;56(8):1069-75. doi: 10.11406/rinketsu.56.1069. Rinsho Ketsueki. 2015. PMID: 26345569 Japanese.

9

[The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma].

Inoue J, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Abe Y, Sekine R, Tsukada N, Hattori Y, Suzuki K. Inoue J, et al. Among authors: abe y. Rinsho Ketsueki. 2015 Nov;56(11):2311-7. doi: 10.11406/rinketsu.56.2311. Rinsho Ketsueki. 2015. PMID: 26666717 Japanese.

10

[Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis during pregnancy].

Ikeda M, Oba R, Yoshiki Y, Shingaki S, Takei T, Miyazaki K, Abe Y, Tsukada N, Ishida T, Suzuki K. Ikeda M, et al. Among authors: abe y. Rinsho Ketsueki. 2017;58(3):216-221. doi: 10.11406/rinketsu.58.216. Rinsho Ketsueki. 2017. PMID: 28381688 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,949 results

Search Page

Filters